Special Issue

Drug Development and Treatment for Neurological Disease

Message from the Guest Editors

We are pleased to invite you to contribute to this Special Issue of *Pharmaceutics* (2021 impact factor: 6.525) entitled "Drug Development and Treatment for Neurological Disease" Neurological disorders and their sequelae (direct consequences) affect as many as one billion people worldwide and include Alzheimer's and Parkinson's disease, epilepsy, autism spectrum disorder, or Brain damage. Novel therapeutic strategies are required which can either prevent or delay the progression of the disease This Special Issue aims to highlight the progress and breakthroughs in drug development and treatment for neurological diseases. Research areas may include, but are not limited to, new drug therapeutic targets and biomarkers, new pathological mechanisms, and novel therapeutic agents in order to provide valuable clues for developing new therapeutic strategies for neurological diseases. In this Special Issue, original research articles and reviews are welcome.

Guest Editors

Prof. Dr. Bassem Sadek

College of Medicine and Health Sciences United Arab Emirates University, Al-Ain, United Arab Emirates

Dr. Amal Akour

Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates

Deadline for manuscript submissions

closed (31 July 2023)

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/
pharmaceutics

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

MDPI